The Hemolytic Uremic Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Hemolytic Uremic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hemolytic Uremic Syndrome. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hemolytic Uremic Syndrome and features dormant and discontinued products.
GlobalData tracks 25 drugs in development for Hemolytic Uremic Syndrome by 22 companies/universities/institutes. The top development phase for Hemolytic Uremic Syndrome is preclinical with nine drugs in that stage. The Hemolytic Uremic Syndrome pipeline has 25 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hemolytic Uremic Syndrome pipeline products market are: Omeros, Eleva and NovelMed Therapeutics.
The key targets in the Hemolytic Uremic Syndrome pipeline products market include Complement C5, Complement Factor B, and Mannan Binding Lectin Serine Protease 2.
The key mechanisms of action in the Hemolytic Uremic Syndrome pipeline product include Complement C5 Inhibitor with ten drugs in Phase III. The Hemolytic Uremic Syndrome pipeline products include three routes of administration with the top ROA being Intravenous and eight key molecule types in the Hemolytic Uremic Syndrome pipeline products market including Monoclonal Antibody, and Small Molecule.
Hemolytic Uremic Syndrome overview
Hemolytic uremic syndrome (HUS) is a rare but serious condition that affects the blood vessels and kidneys. It is caused by the damage and inflammation of small blood vessels, which leads to the formation of blood clots that block the flow of blood and oxygen to the organs. HUS can result in anemia, low platelet count, and kidney failure. The most common cause of HUS is infection with certain strains of Escherichia coli (E. coli) bacteria that produce a toxin called Shiga toxin. These bacteria are usually found in contaminated food or water, especially undercooked meat, unpasteurized milk, or raw fruits and vegetables. Other causes of HUS include other infections, certain medications, pregnancy, cancer, or autoimmune diseases. Most people recover from HUS with proper treatment, but some may have long-term kidney problems or other complications.
For a complete picture of Hemolytic Uremic Syndrome’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
